星空体育官方入口网站网址大全-登录入口官网

[GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2024-7-8：记录最新过程，接近3个月了才送外审，速度真的挺慢了。 Submission received Submission status Date Submission received 11 Apr 2024 Technical check Submission status Date Submission is under technical check 11 Apr 2024 Amendment received 16 Apr 2024 Amendment received 17 Apr 2024 Submission passed technical check 18 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 18 Apr 2024 With editor Submission status Date Editor assigned 02 Jul 2024 Peer review Submission status Date Submission under peer review 08 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊？Technical check已经20天了，中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：Ready for editorial assignment 这个状态1w了，真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：转化医学;综合期刊 经验分享：2023年度影响因子为4.3分，未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向：炎症性肠病 经验分享：接受了，投稿历程发出来给大伙参考一下。 Submission history Publishing and rights Submission status Date Submission is in publishing and rights 21 Feb 2024 Peer review Submission status Date Submission accepted 21 Feb 2024 Submission under peer review 07 Feb 2024 Submission passed technical check 07 Feb 2024 Amendment received 07 Feb 2024 Revision received 31 Jan 2024 Submission under peer review 24 Jan 2024 Submission passed technical check 24 Jan 2024 Revision received 05 Jan 2024 Submission under peer review 30 Sep 2023 Technical check Submission status Date Submission passed technical check 30 Sep 2023 Amendment received 30 Sep 2023 Submission is under technical check 29 Sep 2023 Submission received Submission status Date Submission received 29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1，中科院二区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;肿瘤 经验分享：请问大家，有没有人询问审稿进度之后，给重新指派了个编辑的？ Editor assigned On 27 May, 2024 Editor invited On 28 Mar, 2024 Submission checks complete On 28 Mar, 2024 First submitted to Scientific Reports On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]

2020-06-03 1462b19em97暂无昵称

请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我

84 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2024-7-8：记录最新过程，接近3个月了才送外审，速度真的挺慢了。 Submission received Submission status Date Submission received 11 Apr 2024 Technical check Submission status Date Submission is under technical check 11 Apr 2024 Amendment received 16 Apr 2024 Amendment received 17 Apr 2024 Submission passed technical check 18 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 18 Apr 2024 With editor Submission status Date Editor assigned 02 Jul 2024 Peer review Submission status Date Submission under peer review 08 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊？Technical check已经20天了，中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：Ready for editorial assignment 这个状态1w了，真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：转化医学;综合期刊 经验分享：2023年度影响因子为4.3分，未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向：炎症性肠病 经验分享：接受了，投稿历程发出来给大伙参考一下。 Submission history Publishing and rights Submission status Date Submission is in publishing and rights 21 Feb 2024 Peer review Submission status Date Submission accepted 21 Feb 2024 Submission under peer review 07 Feb 2024 Submission passed technical check 07 Feb 2024 Amendment received 07 Feb 2024 Revision received 31 Jan 2024 Submission under peer review 24 Jan 2024 Submission passed technical check 24 Jan 2024 Revision received 05 Jan 2024 Submission under peer review 30 Sep 2023 Technical check Submission status Date Submission passed technical check 30 Sep 2023 Amendment received 30 Sep 2023 Submission is under technical check 29 Sep 2023 Submission received Submission status Date Submission received 29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1，中科院二区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;肿瘤 经验分享：请问大家，有没有人询问审稿进度之后，给重新指派了个编辑的？ Editor assigned On 27 May, 2024 Editor invited On 28 Mar, 2024 Submission checks complete On 28 Mar, 2024 First submitted to Scientific Reports On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]

2024-07-08 wzt9715 来自广东省

审稿速度:6.0 | 投稿命中率:50.0
经验分享：2024-7-8：记录最新过程，接近3个月了才送外审，速度真的挺慢了。
Submission received
Submission status Date
Submission received 11 Apr 2024
Technical check
Submission status Date
Submission is under technical check 11 Apr 2024
Amendment received 16 Apr 2024
Amendment received 17 Apr 2024
Submission passed technical check 18 Apr 2024
Editorial assignment
Submission status Date
Ready for editorial assignment 18 Apr 2024
With editor
Submission status Date
Editor assigned 02 Jul 2024
Peer review
Submission status Date
Submission under peer review 08 Jul 2024

40 15

展开15条回复

[GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2024-7-8：记录最新过程，接近3个月了才送外审，速度真的挺慢了。 Submission received Submission status Date Submission received 11 Apr 2024 Technical check Submission status Date Submission is under technical check 11 Apr 2024 Amendment received 16 Apr 2024 Amendment received 17 Apr 2024 Submission passed technical check 18 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 18 Apr 2024 With editor Submission status Date Editor assigned 02 Jul 2024 Peer review Submission status Date Submission under peer review 08 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊？Technical check已经20天了，中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：Ready for editorial assignment 这个状态1w了，真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：转化医学;综合期刊 经验分享：2023年度影响因子为4.3分，未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向：炎症性肠病 经验分享：接受了，投稿历程发出来给大伙参考一下。 Submission history Publishing and rights Submission status Date Submission is in publishing and rights 21 Feb 2024 Peer review Submission status Date Submission accepted 21 Feb 2024 Submission under peer review 07 Feb 2024 Submission passed technical check 07 Feb 2024 Amendment received 07 Feb 2024 Revision received 31 Jan 2024 Submission under peer review 24 Jan 2024 Submission passed technical check 24 Jan 2024 Revision received 05 Jan 2024 Submission under peer review 30 Sep 2023 Technical check Submission status Date Submission passed technical check 30 Sep 2023 Amendment received 30 Sep 2023 Submission is under technical check 29 Sep 2023 Submission received Submission status Date Submission received 29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1，中科院二区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;肿瘤 经验分享：请问大家，有没有人询问审稿进度之后，给重新指派了个编辑的？ Editor assigned On 27 May, 2024 Editor invited On 28 Mar, 2024 Submission checks complete On 28 Mar, 2024 First submitted to Scientific Reports On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]

2024-07-17 ms9000000825188207 来自湖北省

请问大家有没有刊物其他联系方式啊？Technical check已经20天了，中间发了两次邮件给srep@nature.com询问情况没有回复

7 0

[GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2024-7-8：记录最新过程，接近3个月了才送外审，速度真的挺慢了。 Submission received Submission status Date Submission received 11 Apr 2024 Technical check Submission status Date Submission is under technical check 11 Apr 2024 Amendment received 16 Apr 2024 Amendment received 17 Apr 2024 Submission passed technical check 18 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 18 Apr 2024 With editor Submission status Date Editor assigned 02 Jul 2024 Peer review Submission status Date Submission under peer review 08 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊？Technical check已经20天了，中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：Ready for editorial assignment 这个状态1w了，真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：转化医学;综合期刊 经验分享：2023年度影响因子为4.3分，未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向：炎症性肠病 经验分享：接受了，投稿历程发出来给大伙参考一下。 Submission history Publishing and rights Submission status Date Submission is in publishing and rights 21 Feb 2024 Peer review Submission status Date Submission accepted 21 Feb 2024 Submission under peer review 07 Feb 2024 Submission passed technical check 07 Feb 2024 Amendment received 07 Feb 2024 Revision received 31 Jan 2024 Submission under peer review 24 Jan 2024 Submission passed technical check 24 Jan 2024 Revision received 05 Jan 2024 Submission under peer review 30 Sep 2023 Technical check Submission status Date Submission passed technical check 30 Sep 2023 Amendment received 30 Sep 2023 Submission is under technical check 29 Sep 2023 Submission received Submission status Date Submission received 29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1，中科院二区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;肿瘤 经验分享：请问大家，有没有人询问审稿进度之后，给重新指派了个编辑的？ Editor assigned On 27 May, 2024 Editor invited On 28 Mar, 2024 Submission checks complete On 28 Mar, 2024 First submitted to Scientific Reports On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]

2023-07-20 ms9000001459812965 来自陕西省

20天了还在技术审查，怎么办

57 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2024-7-8：记录最新过程，接近3个月了才送外审，速度真的挺慢了。 Submission received Submission status Date Submission received 11 Apr 2024 Technical check Submission status Date Submission is under technical check 11 Apr 2024 Amendment received 16 Apr 2024 Amendment received 17 Apr 2024 Submission passed technical check 18 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 18 Apr 2024 With editor Submission status Date Editor assigned 02 Jul 2024 Peer review Submission status Date Submission under peer review 08 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊？Technical check已经20天了，中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：Ready for editorial assignment 这个状态1w了，真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：转化医学;综合期刊 经验分享：2023年度影响因子为4.3分，未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向：炎症性肠病 经验分享：接受了，投稿历程发出来给大伙参考一下。 Submission history Publishing and rights Submission status Date Submission is in publishing and rights 21 Feb 2024 Peer review Submission status Date Submission accepted 21 Feb 2024 Submission under peer review 07 Feb 2024 Submission passed technical check 07 Feb 2024 Amendment received 07 Feb 2024 Revision received 31 Jan 2024 Submission under peer review 24 Jan 2024 Submission passed technical check 24 Jan 2024 Revision received 05 Jan 2024 Submission under peer review 30 Sep 2023 Technical check Submission status Date Submission passed technical check 30 Sep 2023 Amendment received 30 Sep 2023 Submission is under technical check 29 Sep 2023 Submission received Submission status Date Submission received 29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1，中科院二区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;肿瘤 经验分享：请问大家，有没有人询问审稿进度之后，给重新指派了个编辑的？ Editor assigned On 27 May, 2024 Editor invited On 28 Mar, 2024 Submission checks complete On 28 Mar, 2024 First submitted to Scientific Reports On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]

2023-04-02 英雄77 来自吉林省

请问Technical check in progress 这个过程需要多少天？谢谢

84 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2024-7-8：记录最新过程，接近3个月了才送外审，速度真的挺慢了。 Submission received Submission status Date Submission received 11 Apr 2024 Technical check Submission status Date Submission is under technical check 11 Apr 2024 Amendment received 16 Apr 2024 Amendment received 17 Apr 2024 Submission passed technical check 18 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 18 Apr 2024 With editor Submission status Date Editor assigned 02 Jul 2024 Peer review Submission status Date Submission under peer review 08 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊？Technical check已经20天了，中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：Ready for editorial assignment 这个状态1w了，真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：转化医学;综合期刊 经验分享：2023年度影响因子为4.3分，未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向：炎症性肠病 经验分享：接受了，投稿历程发出来给大伙参考一下。 Submission history Publishing and rights Submission status Date Submission is in publishing and rights 21 Feb 2024 Peer review Submission status Date Submission accepted 21 Feb 2024 Submission under peer review 07 Feb 2024 Submission passed technical check 07 Feb 2024 Amendment received 07 Feb 2024 Revision received 31 Jan 2024 Submission under peer review 24 Jan 2024 Submission passed technical check 24 Jan 2024 Revision received 05 Jan 2024 Submission under peer review 30 Sep 2023 Technical check Submission status Date Submission passed technical check 30 Sep 2023 Amendment received 30 Sep 2023 Submission is under technical check 29 Sep 2023 Submission received Submission status Date Submission received 29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1，中科院二区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;肿瘤 经验分享：请问大家，有没有人询问审稿进度之后，给重新指派了个编辑的？ Editor assigned On 27 May, 2024 Editor invited On 28 Mar, 2024 Submission checks complete On 28 Mar, 2024 First submitted to Scientific Reports On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]

2024-07-10 ms3000000691298775 来自江西省

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：临床
经验分享：Ready for editorial assignment 这个状态1w了，真难顶#炎症性肠病患者#

20 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2024-7-8：记录最新过程，接近3个月了才送外审，速度真的挺慢了。 Submission received Submission status Date Submission received 11 Apr 2024 Technical check Submission status Date Submission is under technical check 11 Apr 2024 Amendment received 16 Apr 2024 Amendment received 17 Apr 2024 Submission passed technical check 18 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 18 Apr 2024 With editor Submission status Date Editor assigned 02 Jul 2024 Peer review Submission status Date Submission under peer review 08 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊？Technical check已经20天了，中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：Ready for editorial assignment 这个状态1w了，真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：转化医学;综合期刊 经验分享：2023年度影响因子为4.3分，未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向：炎症性肠病 经验分享：接受了，投稿历程发出来给大伙参考一下。 Submission history Publishing and rights Submission status Date Submission is in publishing and rights 21 Feb 2024 Peer review Submission status Date Submission accepted 21 Feb 2024 Submission under peer review 07 Feb 2024 Submission passed technical check 07 Feb 2024 Amendment received 07 Feb 2024 Revision received 31 Jan 2024 Submission under peer review 24 Jan 2024 Submission passed technical check 24 Jan 2024 Revision received 05 Jan 2024 Submission under peer review 30 Sep 2023 Technical check Submission status Date Submission passed technical check 30 Sep 2023 Amendment received 30 Sep 2023 Submission is under technical check 29 Sep 2023 Submission received Submission status Date Submission received 29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1，中科院二区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;肿瘤 经验分享：请问大家，有没有人询问审稿进度之后，给重新指派了个编辑的？ Editor assigned On 27 May, 2024 Editor invited On 28 Mar, 2024 Submission checks complete On 28 Mar, 2024 First submitted to Scientific Reports On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]

2024-06-22 侠胆医心来自威斯康星

审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向：转化医学;综合期刊
经验分享：2023年度影响因子为4.3分，未来估计在3.5-4.5之间

30 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2024-7-8：记录最新过程，接近3个月了才送外审，速度真的挺慢了。 Submission received Submission status Date Submission received 11 Apr 2024 Technical check Submission status Date Submission is under technical check 11 Apr 2024 Amendment received 16 Apr 2024 Amendment received 17 Apr 2024 Submission passed technical check 18 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 18 Apr 2024 With editor Submission status Date Editor assigned 02 Jul 2024 Peer review Submission status Date Submission under peer review 08 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊？Technical check已经20天了，中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：Ready for editorial assignment 这个状态1w了，真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：转化医学;综合期刊 经验分享：2023年度影响因子为4.3分，未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向：炎症性肠病 经验分享：接受了，投稿历程发出来给大伙参考一下。 Submission history Publishing and rights Submission status Date Submission is in publishing and rights 21 Feb 2024 Peer review Submission status Date Submission accepted 21 Feb 2024 Submission under peer review 07 Feb 2024 Submission passed technical check 07 Feb 2024 Amendment received 07 Feb 2024 Revision received 31 Jan 2024 Submission under peer review 24 Jan 2024 Submission passed technical check 24 Jan 2024 Revision received 05 Jan 2024 Submission under peer review 30 Sep 2023 Technical check Submission status Date Submission passed technical check 30 Sep 2023 Amendment received 30 Sep 2023 Submission is under technical check 29 Sep 2023 Submission received Submission status Date Submission received 29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1，中科院二区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;肿瘤 经验分享：请问大家，有没有人询问审稿进度之后，给重新指派了个编辑的？ Editor assigned On 27 May, 2024 Editor invited On 28 Mar, 2024 Submission checks complete On 28 Mar, 2024 First submitted to Scientific Reports On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]

2024-02-21 超超不吵吵来自湖南省

偏重的研究方向：炎症性肠病
经验分享：接受了，投稿历程发出来给大伙参考一下。
Submission history
Publishing and rights
Submission status Date
Submission is in publishing and rights
21 Feb 2024
Peer review
Submission status Date
Submission accepted
21 Feb 2024
Submission under peer review
07 Feb 2024
Submission passed technical check
07 Feb 2024
Amendment received
07 Feb 2024
Revision received
31 Jan 2024
Submission under peer review
24 Jan 2024
Submission passed technical check
24 Jan 2024
Revision received
05 Jan 2024
Submission under peer review
30 Sep 2023
Technical check
Submission status Date
Submission passed technical check
30 Sep 2023
Amendment received
30 Sep 2023
Submission is under technical check
29 Sep 2023
Submission received
Submission status Date
Submission received
29 Sep 2023

44 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2024-7-8：记录最新过程，接近3个月了才送外审，速度真的挺慢了。 Submission received Submission status Date Submission received 11 Apr 2024 Technical check Submission status Date Submission is under technical check 11 Apr 2024 Amendment received 16 Apr 2024 Amendment received 17 Apr 2024 Submission passed technical check 18 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 18 Apr 2024 With editor Submission status Date Editor assigned 02 Jul 2024 Peer review Submission status Date Submission under peer review 08 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊？Technical check已经20天了，中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：Ready for editorial assignment 这个状态1w了，真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：转化医学;综合期刊 经验分享：2023年度影响因子为4.3分，未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向：炎症性肠病 经验分享：接受了，投稿历程发出来给大伙参考一下。 Submission history Publishing and rights Submission status Date Submission is in publishing and rights 21 Feb 2024 Peer review Submission status Date Submission accepted 21 Feb 2024 Submission under peer review 07 Feb 2024 Submission passed technical check 07 Feb 2024 Amendment received 07 Feb 2024 Revision received 31 Jan 2024 Submission under peer review 24 Jan 2024 Submission passed technical check 24 Jan 2024 Revision received 05 Jan 2024 Submission under peer review 30 Sep 2023 Technical check Submission status Date Submission passed technical check 30 Sep 2023 Amendment received 30 Sep 2023 Submission is under technical check 29 Sep 2023 Submission received Submission status Date Submission received 29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1，中科院二区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;肿瘤 经验分享：请问大家，有没有人询问审稿进度之后，给重新指派了个编辑的？ Editor assigned On 27 May, 2024 Editor invited On 28 Mar, 2024 Submission checks complete On 28 Mar, 2024 First submitted to Scientific Reports On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]

2024-07-03 清清欢来自江西省

现在是JCR Q1，中科院二区吗？

21 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2024-7-8：记录最新过程，接近3个月了才送外审，速度真的挺慢了。 Submission received Submission status Date Submission received 11 Apr 2024 Technical check Submission status Date Submission is under technical check 11 Apr 2024 Amendment received 16 Apr 2024 Amendment received 17 Apr 2024 Submission passed technical check 18 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 18 Apr 2024 With editor Submission status Date Editor assigned 02 Jul 2024 Peer review Submission status Date Submission under peer review 08 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊？Technical check已经20天了，中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：Ready for editorial assignment 这个状态1w了，真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：转化医学;综合期刊 经验分享：2023年度影响因子为4.3分，未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向：炎症性肠病 经验分享：接受了，投稿历程发出来给大伙参考一下。 Submission history Publishing and rights Submission status Date Submission is in publishing and rights 21 Feb 2024 Peer review Submission status Date Submission accepted 21 Feb 2024 Submission under peer review 07 Feb 2024 Submission passed technical check 07 Feb 2024 Amendment received 07 Feb 2024 Revision received 31 Jan 2024 Submission under peer review 24 Jan 2024 Submission passed technical check 24 Jan 2024 Revision received 05 Jan 2024 Submission under peer review 30 Sep 2023 Technical check Submission status Date Submission passed technical check 30 Sep 2023 Amendment received 30 Sep 2023 Submission is under technical check 29 Sep 2023 Submission received Submission status Date Submission received 29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1，中科院二区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;肿瘤 经验分享：请问大家，有没有人询问审稿进度之后，给重新指派了个编辑的？ Editor assigned On 27 May, 2024 Editor invited On 28 Mar, 2024 Submission checks complete On 28 Mar, 2024 First submitted to Scientific Reports On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]

2024-05-27 ms7000000411552686 来自甘肃省

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：免疫;肿瘤
经验分享：请问大家，有没有人询问审稿进度之后，给重新指派了个编辑的？
Editor assigned
On 27 May, 2024
Editor invited
On 28 Mar, 2024
Submission checks complete
On 28 Mar, 2024
First submitted to Scientific Reports
On 15 Mar, 2024

34 5

展开5条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务